Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

DM199

Recombinant protein · developed by DiaMedica Therapeutics

Phase 2 Most advanced trial (none active)

DMAC Developer

1 Registered trials

What is DM199?

DM199 is a recombinant human tissue kallikrein-1 (rhKLK-1) protein administered by injection. It is being studied in kidney diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Recombinant protein
Therapy area: Renal & urology
Developer: DiaMedica Therapeutics Inc (DMAC)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 2
UNII: H6Y3CRX3LC

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT04123613	Phase 2	Kidney Diseases	Completed	DMAC

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Kidney Diseases

More from DiaMedica Therapeutics

Human tissue kallikrein Phase 2/3

Sources

ClinicalTrials.gov NCT04123613

Updated Oct 3, 2026. Something wrong or missing? Report it on the DMAC page.

Follow DMAC, the company behind DM199

See DMAC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

DMAC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z